Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Change in Accured Expenses (2016 - 2025)

Medifast (MED) has disclosed Change in Accured Expenses for 16 consecutive years, with -$4.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 61.65% year-over-year to -$4.3 million, compared with a TTM value of -$23.9 million through Dec 2025, up 31.67%, and an annual FY2025 reading of -$23.9 million, up 31.67% over the prior year.
  • Change in Accured Expenses was -$4.3 million for Q4 2025 at Medifast, down from -$516000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $29.2 million in Q1 2021 and bottomed at -$21.9 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$3.9 million, with a median of -$5.2 million recorded in 2024.
  • The sharpest move saw Change in Accured Expenses surged 1582.14% in 2021, then tumbled 2982.14% in 2024.
  • Year by year, Change in Accured Expenses stood at $11.6 million in 2021, then crashed by 231.82% to -$15.3 million in 2022, then skyrocketed by 97.63% to -$364000.0 in 2023, then crashed by 2982.14% to -$11.2 million in 2024, then surged by 61.65% to -$4.3 million in 2025.
  • Business Quant data shows Change in Accured Expenses for MED at -$4.3 million in Q4 2025, -$516000.0 in Q3 2025, and -$13.1 million in Q2 2025.